6TH EDUCATIONAL IGCLL WORKSHOP

22-23 SEPTEMBER 2016, UPPSALA UNIVERSITY, UPPSALA (SWEDEN)

  • Welcome (L. Sutton)
  • B cell receptor signaling pathways in health and disease (D. Efremov)
  • Immunogenetics in CLL: the last 20 years (L. Sutton)
  • Mechanisms of immunoglobulin diversity (F. Davi)
  • From the patient to the sequence: Primers, PCR, Detection of clonality, Sequencing (A. Langerak))
  • IMGT tools for Interpretation of IG sequences and NGS repertoires: 2016 novelties (V. Giudicelli)
  • BcR IG Stereotyp: Identifying CLL subsets (A. Agathangelidis)
  • Hands on exercises (V. Bikos)
  • CLL genetics and prognostication (R. Rosenquist)
  • Targeting signaling pathways for treating CLL (P. Ghia)
  • Technical considerations for NGS analysis of immunoglublin gene repertoires (A. Vardi)
  • Bioinformatics: State-of-art tools for NGS immunogenetics (N. Darzentas)
  • MRD in CLL (A. Rawstron)
  • More info

41ST GENERAL ASSEMBLY OF ERIC MEMBERS AT THE 21ST CONGRESS OF EHA

9-12 JUNE 2016, BELLA CENTER, COPENHAGEN (DENMARK)

  • Agenda
  • Introduction (P. Ghia)
  • Completion of EBMT Survey (P. Dreger)
  • Update on the BR Study (A. Cuneo)
  • Minimal data set project (C. Moreno)
  • Complex Karyotype in CLL (A. Kater)
  • TP53 Certification overview and results from round 3 (S. Pospíšilová / J. Malčíková)
  • IgCLL Workshop in Uppsala (L. Sutton)
  • ERIC Funding activities (K. Stamatopoulos)
  • Proposed Minimum Panel for Diagnosis (A. Rawstron)
  • ERIC – SWG Meeting – Dissecting and understanding inter- and intratumoral heterangenity in CLL (C. Wu)

4OTH GENERAL ASSEMBLY OF ERIC MEMBERS AT THE 13TH ANNUAL SYMPOSIUM OF THE ELN

2-3 FEBRUARY 2016, CONGRESS CENTRE ROSENGARTEN, MANNHEIM (GERMANY)

  • Agenda
  • General Information (P. Ghia)
  • Reproducible diagnosis of CLL by flow cytometry (A. Rawstron)
  • The IG network (A. Hadzidimitriou)
  • TP53 network activities (S. Pospíšilová)
  • TP53 certification update (J. Malčíková)
  • Interpretation of karyotyping using mitogens vs. FISH vs. SNP based array CLL (A. Kater)
  • Role of alloSCT in the targeted therapy area: an international prospective alloSCT study proposal (M. van Gelder)